Jci_page_head_homepage_01 Jci_page_head_homepage_02
Koji Kishimoto, Victor M. Dong, Shohreh Issazadeh, Eugenia V. Fedoseyeva, Ana Maria Waaga, Akira Yamada, Masayuki Sho, Gilles Benichou, Hugh Auchincloss Jr., Michael J. Grusby, Samia J. Khoury, Mohamed H. Sayegh
Published in Volume 106, Issue 1
J Clin Invest. 2000; 106(1):63–72 doi:10.1172/JCI9586
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 4

Effect of MR1 or CTLA4Ig treatment on cardiac allograft survival in wild-type (a) or CD28–/– mice (b). Recipients were treated with MR1 (250 μg intraperitoneally) on the day of transplantation or with CTLA4Ig (250 μg intraperitoneally) on day 2. Untreated controls are shown by solid line. AP < 0.01; BP = 0.33.